Skip to main content
. Author manuscript; available in PMC: 2019 Apr 1.
Published in final edited form as: J Neurooncol. 2018 Jan 4;137(2):249–257. doi: 10.1007/s11060-017-2732-1

Figure 3. Effect of Mutated versus Wild-Type ATRX on Immune Marker Expression.

Figure 3

A. GBM samples were tested for immune marker expression by IHC and compared based on ATRX mutant status. CD3 was significantly higher in ATRX mutated tumors (p=0.0306) shown as an odds ratio of greater than 1. B. TCGA analysis of GBM samples revealed that CD3 (p=0.0043), CD8 (p=0.0011), CD70 (p=0.0060), CD163 (p=0.0135), CD274 (gene for PD-L1) (p=0.0229), and PDCD1 (gene for PD-1) (p=0.0101) were lower in ATRX mutated tumors.

Circled odds ratio or mean ratio point estimates differ significantly from one at α=0.05.